期刊文献+

卡托普利联合缬沙坦在慢性充血性心力衰竭中的效果分析 被引量:1

下载PDF
导出
摘要 目的:探讨卡托普利联合缬沙坦在慢性充血性心力衰竭中的效果。方法:选择慢性充血性心力衰竭患者共100例,随机分为两组:观察组和对照组。两组患者均给予强心类药物、利尿剂、硝酸酯类药物等抗心力衰竭常规治疗,对照组患者同时给予卡托普利口服,观察组同时给予卡托普利和缬沙坦治疗。观察两组患者治疗前后心功能指标改变情况,主要观察左心室舒张末期内径、左室射血分数改变情况,对两组治疗后进行疗效评定。结果:观察组治疗后左心室舒张末期内径、左室射血分数与对照组治疗后比较,差异有统计学意义(P<0.05)。观察组总有效率为94.0%,对照组总有效率为78.0%,观察组总有效率高于对照组,差异有统计学意义(P<0.05)。结论:卡托普利联合缬沙坦在慢性充血性心力衰竭中的治疗效果显著,能够显著改善患者心功能,值得借鉴。
作者 李涛 杨丽娜
出处 《吉林医学》 CAS 2013年第20期4057-4058,共2页 Jilin Medical Journal
  • 相关文献

参考文献3

二级参考文献29

  • 1吕卓人,梁磊,艾文婷.血管紧张素Ⅱ1型受体拮抗剂研究进展[J].中华心血管病杂志,2004,32(11):1054-1056. 被引量:61
  • 2罗杰.血管紧张素Ⅱ在人阻力动脉生成的双重途径:血管紧张素Ⅱ受体拮抗剂和转换酶抑制剂的治疗[J].国外医学.心血管疾病分册,2001,28(1):46-47.
  • 3[1]Macdonald PS,Hill J,Krum H.COLA Ⅱ Investigators.The impact of baseline HR and BP on the tolerability of carvedilol in the elderly:the COLA (Carvedilol Open Label Assessment) Ⅱ Study[J].Am J Cardiovasc Drugs,2006,6(6):401-405.
  • 4[2]Dobre D,van Veldhuisen DJ.SENIORS Investigators.Tolerability and dose-related effects of nebivolol in elderly patients with heart failure:data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial[J].Am Heart J,2007,154 (1):109-115.
  • 5[3]Willenheimer R,van Veldhuisen DJ,CIBIS Ⅲ Investigators.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) Ⅲ.Circulation,2005,112(16):2426-2435.
  • 6[4]Chuen M J,MacFadyen RJ.Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure[J].Am J Cardiol,2006,98(10):1416-1417.
  • 7[5]Gheorghiade M,Konstam MA,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Shortterm clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297 (12):1332-1343.
  • 8[6]Konstam MA,Gheorghiade M,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial[J].JAMA,2007,297(12):1319-1331.
  • 9[7]Cleland JG,Coletta AP,Clark AL.Clinical trials update from the American College of Cardiology 2007:ALPHA,EVEREST,FUSION Ⅱ,VALIDD,PARR-2,REMODEL,SPICE,COURAGE,COACH,REMADHE,pro-BNP for the evaluation of dyspnoea and THIS-diet[J].Eur J Heart Fail,2007,9(6-7):740-745.
  • 10[8]Go AS,Lee WY,Yang J,et al.Statin therapy and risks for death and hospitalization in chronic heart failure[J].JAMA.2006,296(17):2105-2111.

共引文献28

同被引文献11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部